Press coverage about Amedica (NASDAQ:AMDA) has been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amedica earned a news impact score of 0.06 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 46.1539795821639 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Several analysts have weighed in on AMDA shares. Maxim Group reaffirmed a “hold” rating on shares of Amedica in a research report on Tuesday, May 8th. ValuEngine raised Amedica from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Shares of Amedica traded down $0.02, hitting $1.09, during trading hours on Thursday, MarketBeat Ratings reports. 112,334 shares of the company’s stock traded hands, compared to its average volume of 635,225. Amedica has a 12-month low of $1.02 and a 12-month high of $6.96.
Amedica Corporation, a biomaterial company, develops, manufactures, and commercializes a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. The company offers silicon nitride implants to surgeons and hospitals for use in cervical and thoracolumbar spine surgery under the Valeo brand.
Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with MarketBeat.com's FREE daily email newsletter.